1stOncology™: Cancer Intelligence Service – Page 11170 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference

On February 22, 2021 Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, reported that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the 7th Annual Immuno-Oncology 360° Conference on February 25, 2021 (Press release, Cue Biopharma, FEB 22, 2021, View Source [SID1234608292]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation Details
Title: Next Generation Synthetic Vaccines
Immuno-STATs: Drugging the Tumor-specific T-cell Repertoire
Date and Time: Thursday, February 25, 2021 at 10:45 a.m. EST

Dr. Suri will present an overview of the Immuno-STAT (Selective Targeting and Alteration of T cells) platform and its next generation derivative, Neo-STAT. He will also highlight the IL-2 based CUE-100 series Immuno-STATs exemplified by CUE-101, the Company’s lead clinical candidate for HPV+ R/M HNSCC and CUE-102, our second drug program designed to target Wilms’ tumor 1 (WT1) specific T cells for the treatment of patients with solid and hematological cancers. The overview will include data supporting mechanistic advantages of the Immuno-STAT and Neo-STAT approach to targeting and activating disease-relevant T cells directly in the patient’s body.

Panel Details
Title: Vaccine Expert Discussion
Date and Time: Thursday, February 25, 2021 at 11:30 a.m. EST

About Immuno-STAT
The company’s Immuno-STAT (Selective Targeting and Alteration of T cells) biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a pMHC to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.

The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drug candidates are delivered directly in the patient’s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients’ T cells to be extracted, modified outside the body (ex vivo), and reinfused.

Micronoma Closes $3.5M Convertible Debt Financing Round

On February 22, 2021 Micronoma, a San Diego, Calif.-based cancer detection biotech company reported that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, closed a $3.5m convertible debt financing round (Press release, Micronoma, FEB 22, 2021, View Source [SID1234578332]).

Backers included SymBiosis, LLC, and The Seerave Foundation. The investments bring the company’s total amount of funding to $6.5m since the first seed round six months ago.

Led by Sandrine Miller-Montgomery, CEO, Micronoma decrypts signals from some of the most ancient matter in the world, the microbiome, to detect cancer early, from all genomes.

The company intends to use the funds to complete its validation study on lung cancer prediction, set up CLIA (Clinical Laboratory Improvement Amendments) operations, establish its go-to-market strategy utilizing its Oncobiota platform, and initiate work on a second cancer target.

Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis

On February 22, 2021 Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, reported that it has entered into an exclusive license agreement with Washington University in St. Louis, one of the world’s leading research institutions, for the development of Wugen’s Memory Natural Killer (NK) Cell program (Press release, Wugen, FEB 22, 2021, View Source [SID1234576287]).

While currently approved autologous cellular therapies have been shown to effectively treat B cell cancers, there remains significant unmet need for treating other cancers, including solid tumors. Memory NK cells have been demonstrated in the clinic to be safe and effective, with several significant advantages over existing therapies. By dovetailing its extensive experience in developing "off-the-shelf" CAR-T with Memory NK cells, Wugen will be able to rapidly deliver its off-the-shelf Memory NK platform to patients.

Todd Fehniger, M.D., Ph.D., Professor of Medicine, Oncology Division, at Washington University and a cellular therapy and transplantation specialist, will be leading these efforts. "Wugen’s Memory Natural Killer (NK) Cell-based therapy program will open up new avenues to explore treatment options for incurable and intractable diseases such as Acute Myeloid Leukemia and Multiple Myeloma, for which current treatment options have limited or no benefit," said Dr. Fehniger. "I look forward to partnering with Wugen to advance these NK cell programs and deliver these much-needed solutions to patients worldwide, and to also expand the impact of memory NK cells to solid tumor immunotherapy."

"This agreement expands our ongoing collaboration with one of the leading research institutions to develop cutting edge cell therapies to treat solid and hematological cancers," said John McKearn, Ph.D., CEO of Wugen. "Our innovative approach is aimed to treat patients who currently lack therapeutic options."

Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs

On February 22, 2021 Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, reported the appointment of Jan Davidson M.D., Ph.D., as the company’s Chief Medical Officer (CMO) (Press release, Wugen, FEB 22, 2021, View Source [SID1234576286]). A leader in oncology research and development, Dr. Davidson has a firsthand understanding of successful design and implementation of oncology clinical trials and expansive immuno-oncology research experience across a variety of cancers. In his CMO position at Wugen, he will be steering the company’s global clinical initiatives targeting solid and liquid tumors.

"Jan will be an invaluable asset to the Wugen as we continue to develop and expand our clinical footprint. His experience in oncology clinical trials and seeing them through to successful execution will provide critical support in advancing Wugen’s candidates through the clinic," said John McKearn, Ph.D., CEO of Wugen. "Jan will be guiding the team to achieve the ultimate goal of creating effective therapies for cancer patients."

Dr. Davidson adds, "I look forward to advancing Wugen’s novel cell therapy platform through clinical testing, and anticipate bringing our transformative Memory NK and T cell programs into tangible clinical treatments, with the goal of addressing the unmet needs of patients suffering from difficult-to-treat solid and hematologic malignancies."

In his most recent most role as Senior Director for Clinical Research at Macrogenics, Dr. Davidson oversaw the company’s translational and clinical research efforts. Prior to MacroGenics, Dr. Davidson conducted clinical research at the National Heart and Lung Institute at National Institutes of Health (NIH) where he investigated NK cell ontogeny and subtypes. Dr. Davidson was the attending physician at Walter Reed National Military Medical Center’s Murth Cancer Center before joining the biotech industry. His substantial research and medical career saw him in senior positions at NHLBI Bone Marrow Transplant Service, Center for Human Immunology and the National Cancer Institute of the NIH, Montefiore Medical Center and The Rockefeller University Hospital among others. He is a physician-scientist with numerous research grants and awards under his name. Dr. Davidson received his MBBS and his Ph.D. in Molecular Medicine from the University College London, University of London in the UK.

Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update

On February 22, 2021 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), reported that it has scheduled its fourth quarter and year end 2020 financial results and corporate update for Thursday, March 4, 2021 (Press release, Arbutus Biopharma, FEB 22, 2021, View Source [SID1234576183]). The schedule for the press release and conference call/webcast are as follows:

•Q4 and Year End 2020 Press Release: March 4, 2021 at 7:30 a.m. ET
•Q4 and Year End 2020 Conference Call/Webcast: March 4, 2021 at 8:45 a.m. ET
•Domestic Dial-In Number: (866) 393-1607
•International Dial-In Number: (914) 495-8556
•Conference ID Number: 4084504
A live webcast of the conference call can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com or directly at Live Webcast.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4084504.